Clinical Trials Logo

Resectable Mass clinical trials

View clinical trials related to Resectable Mass.

Filter by:
  • None
  • Page 1

NCT ID: NCT04029857 Withdrawn - Clinical trials for Clinical Stage III Esophageal Adenocarcinoma AJCC v8

Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery

Start date: March 14, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies nutritional supplementation with Impact Advanced Recovery to see how well it works compared with standard nutritional supplementation in reducing complications in patients with esophageal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who are undergoing chemotherapy, radiation therapy, and/or surgery. Impact Advanced Recovery may help to reduce the number of surgical complications, reduce toxicity, improve nutritional status before surgery, and reduce morbidity after surgery in patients with esophageal cancer.

NCT ID: NCT02754856 Completed - Clinical trials for Stage IV Colorectal Cancer AJCC v7

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Start date: July 28, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and how well tremelimumab and durvalumab work in treating patients with colorectal cancer that has spread to the liver and can be removed by surgery. Immunotherapy with monoclonal antibodies, such as tremelimumab and durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.